Classification In Accordance With Article 12, Paragraph 5, Reads November 8, 2012, # 189, Of Certain Medicinal Products For Human Use, Approved Conprocedura Centralised. (Resolution No. 1445/2014).

Original Language Title: Classificazione, ai sensi dell'articolo 12, comma 5, legge 8 novembre2012, n. 189, di taluni medicinali per uso umano, approvati conprocedura centralizzata. (Determina n. 1445/2014).

Read the untranslated law here: http://www.gazzettaufficiale.it/atto/serie_generale/caricaArticoloDefault/originario?atto.dataPubblicazioneGazzetta=2015-01-03&atto.codiceRedazionale=14A10051&elenco30giorni=false&atto.tipoProvvedimento=DECRETO

The DIRECTOR-GENERAL having regard to articles 8 and 9 of legislative decree July 30, 1999, # 300; Visto l'art. September 30, 2003, 48, of Decree-Law n. 269, converted into law November 24, 2003, n. 326, establishing the Italian medicines agency; Having regard to law No 537 as amended December 24, 1993 with particular reference to art. 8, subparagraph 10 (c)); Having regard to the Decree of the Minister of health in consultation with the Ministers for public administration and Economics and finance dated September 20, 2004, n. 245 laying down rules on the organisation and the functioning of the Italian Medicines Agency, pursuant to paragraph 13, art. 48 above, as amended by Decree No. 53 of the Minister of health, in consultation with the Ministers for public administration and simplification and of economy and Finance of the March 29, 2012; Having regard to the Decree of the Minister of health November 8, 2011, recorded at the Registry Office of the budget "visas", sheet # 1282 of November 14, 2011, with which he was appointed Director General of the Italian Medicines Agency. Luca Pani, as of November 16, 2011; Having regard to Decree-Law No 158 September 13, 2012, converted, with amendments by law November 8, 2012 # 189, containing "urgent provisions to promote the development of the country through a higher level of health protection and, in particular, article. 12, paragraph 5; Having regard to Council Regulation (EC) No 726/2004 of the European Parliament and of the Council of March 31, 2004, laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency; Having regard to Council Regulation (EC) No 1901/2006 of the European Parliament and of the Council of December 12, 2006 on medicinal products for paediatric use amending Council Regulation (EEC) No. 1768/92 of Directive 2001/20/EC and Regulation (EC) No. 726/2004; Having regard to the Legislative Decree of April 24, 2006, n. 219, published in the official journal of the Italian Republic No. 142 of June 21, 2001, concerning the implementation of Directive 2001/83/EC, as amended, on the Community code relating to medicinal products for human use, as well as of Directive 2003/94/EC; Having regard to Council Regulation (EC) no 1394/2007 of the European Parliament and of the Council of November 13, 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004; Having regard to the official journal of the European Union of October 31, 2014 reporting the summary of decisions of the European Union concerning the marketing authorisation of medicinal products from 1 September to September 30, 2014; Having regard to the opinion on the system of classification for the purpose of expressing, on a proposal from the European Commission's Scientific, Technical Assessment Office (CTS) of AIFA on November 11, 2014;
Causes: The packaging of the following medicinal products for human use, generic/equivalents/Biosimilars of reauthorization, accompanied by A.I.C. and classification number for the purpose of: ABASRIA;
ACCOFIL;
BUSULFAN FRESENIUS KABI;
CLOPIDOGREL/ACETYLSALICYLIC ACID TEVA. Described in detail in the annex, which forms an integral part of this provision, are placed in a special section of the class referred to in art. 12, paragraph 5, of law November 8, 2012 # 189, called class C (nn), dedicated to drugs not yet evaluated for the purposes of new listings, pending the presentation by the company concerned of a possible application for different classification. The holder of A. I.c., before the start of the marketing must have observed, where applicable, conditions or restrictions with regard to the safe and effective use of the medicinal product and must inform the AIFA-Office Prices ex factory price, refund-& retail price and the start date for the marketing of the medicinal product. This resolution shall enter into force on the day following its publication in the Official Gazette.
Rome, December 9, 2014 General Manager: Pani